Special Issue

Advances of Skin Disease

Message from the Guest Editor

The skin represents the most exposed barrier of organisms, and, as such, has been the subject of intensive research focused on both neoplastic and inflammatory conditions. Recently, personalized therapies have gained attention not only on the scientific level, but also on the clinical level. These therapies have revolutionized oncology, with melanoma being the most explored cutaneous disease, by the use of new, cuttingedge treatments, including immunotherapies and targeted therapies. This proposed Special Issue aims to collect the most recent insights into clinical and translational research regarding melanoma. nonmelanoma skin neoplasms, and inflammatory cutaneous conditions. The scope of the research includes studies with novel diagnostic or therapeutic approaches that can result in more personalized and efficient cutaneous medicine, including molecular/cellular mechanisms, detection, stratification, surveillance, care management, or treatment of cutaneous diseases.

Guest Editor

Dr. Jorge Feito

Pathology Department, Complejo Asistencial Universitario de Salamanca, 37007 Salamanca, Spain

Deadline for manuscript submissions

closed (10 May 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/118734

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

